Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome.
Oleksandr OliynykWojciech BargAnna SlifirczykYanina OliynykVitaliy GurianovMarta RoratPublished in: Viruses (2021)
Tocilizumab therapy in patients with COVID-19 and CRS was associated with increased mortality, while in MAS patients, it contributed to reduced mortality.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- cardiovascular events
- chronic kidney disease
- ejection fraction
- sars cov
- newly diagnosed
- juvenile idiopathic arthritis
- risk factors
- prognostic factors
- peritoneal dialysis
- stem cells
- cardiovascular disease
- coronary artery disease
- type diabetes
- patient reported outcomes
- mesenchymal stem cells